Regulation of angiotensin II receptor expression by nitric oxide in rat adrenal gland

Makoto Usui, Toshihiro Ichiki, Makoto Katoh, Kensuke Egashira, Akira Takeshita

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

We recently reported that administration of N(ω)-nitro-L-arginine methyl ester (L-NAME), an inhibitor of nitric oxide (NO) production, activates the vascular and cardiac renin-angiotensin systems and causes vascular thickening and myocardial hypertrophy in rats with perivascular and myocardial fibrosis. It has been reported that aldosterone may contribute to the development of cardiac fibrosis, but it is not known whether inhibition of NO synthesis affects angiotensin II (Ang II) receptor gene expression and aldosterone secretion. The aim of this study Was to investigate the effect of NO inhibition on the expression of Ang II receptors in the adrenal gland and on aldosterone secretion in rats. Wistar King A rats received normal water, L-NAME alone (1 mg/mL in the drinking water), or L-NAME and the α1- adrenergic receptor blocker bunazosin (0.1 mg/mL in the drinking water) for 1 week. After 1 week of treatment with L-NAME, systolic blood pressure, plasma aldosterone concentration (PAC), and mRNA level and number of Ang II type 1 receptor (AT1-R) were increased. Plasma renin activity, serum angiotensin- converting enzyme activity, and the number of AT2-R were unchanged. Although addition of bunazosin to L-NAME restored systolic blood pressure to the control level, PAC and AT1-R numbers remained significantly higher than those of control level. These results suggest that the increased AT1-R number and PAC induced by the inhibition of NO synthesis were independent of blood pressure and systemic renin-angiotensin system. Therefore, hypertension and myocardial fibrosis induced by NO blockade may be due in part to an elevation of PAC caused by increased AT1-R in the adrenal gland.

Original languageEnglish
Pages (from-to)527-533
Number of pages7
JournalHypertension
Volume32
Issue number3
DOIs
Publication statusPublished - Jan 1 1998

Fingerprint

Angiotensin Receptors
Adrenal Glands
Aldosterone
Nitric Oxide
NG-Nitroarginine Methyl Ester
Blood Pressure
Fibrosis
Renin-Angiotensin System
Drinking Water
Blood Vessels
Angiotensin Type 1 Receptor
Adrenergic Antagonists
Peptidyl-Dipeptidase A
Renin
Adrenergic Receptors
Hypertrophy
Hypertension
Gene Expression
Messenger RNA
Water

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

Regulation of angiotensin II receptor expression by nitric oxide in rat adrenal gland. / Usui, Makoto; Ichiki, Toshihiro; Katoh, Makoto; Egashira, Kensuke; Takeshita, Akira.

In: Hypertension, Vol. 32, No. 3, 01.01.1998, p. 527-533.

Research output: Contribution to journalArticle

Usui, Makoto ; Ichiki, Toshihiro ; Katoh, Makoto ; Egashira, Kensuke ; Takeshita, Akira. / Regulation of angiotensin II receptor expression by nitric oxide in rat adrenal gland. In: Hypertension. 1998 ; Vol. 32, No. 3. pp. 527-533.
@article{e03c8c37e7e448caacce3454b27a0083,
title = "Regulation of angiotensin II receptor expression by nitric oxide in rat adrenal gland",
abstract = "We recently reported that administration of N(ω)-nitro-L-arginine methyl ester (L-NAME), an inhibitor of nitric oxide (NO) production, activates the vascular and cardiac renin-angiotensin systems and causes vascular thickening and myocardial hypertrophy in rats with perivascular and myocardial fibrosis. It has been reported that aldosterone may contribute to the development of cardiac fibrosis, but it is not known whether inhibition of NO synthesis affects angiotensin II (Ang II) receptor gene expression and aldosterone secretion. The aim of this study Was to investigate the effect of NO inhibition on the expression of Ang II receptors in the adrenal gland and on aldosterone secretion in rats. Wistar King A rats received normal water, L-NAME alone (1 mg/mL in the drinking water), or L-NAME and the α1- adrenergic receptor blocker bunazosin (0.1 mg/mL in the drinking water) for 1 week. After 1 week of treatment with L-NAME, systolic blood pressure, plasma aldosterone concentration (PAC), and mRNA level and number of Ang II type 1 receptor (AT1-R) were increased. Plasma renin activity, serum angiotensin- converting enzyme activity, and the number of AT2-R were unchanged. Although addition of bunazosin to L-NAME restored systolic blood pressure to the control level, PAC and AT1-R numbers remained significantly higher than those of control level. These results suggest that the increased AT1-R number and PAC induced by the inhibition of NO synthesis were independent of blood pressure and systemic renin-angiotensin system. Therefore, hypertension and myocardial fibrosis induced by NO blockade may be due in part to an elevation of PAC caused by increased AT1-R in the adrenal gland.",
author = "Makoto Usui and Toshihiro Ichiki and Makoto Katoh and Kensuke Egashira and Akira Takeshita",
year = "1998",
month = "1",
day = "1",
doi = "10.1161/01.HYP.32.3.527",
language = "English",
volume = "32",
pages = "527--533",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Regulation of angiotensin II receptor expression by nitric oxide in rat adrenal gland

AU - Usui, Makoto

AU - Ichiki, Toshihiro

AU - Katoh, Makoto

AU - Egashira, Kensuke

AU - Takeshita, Akira

PY - 1998/1/1

Y1 - 1998/1/1

N2 - We recently reported that administration of N(ω)-nitro-L-arginine methyl ester (L-NAME), an inhibitor of nitric oxide (NO) production, activates the vascular and cardiac renin-angiotensin systems and causes vascular thickening and myocardial hypertrophy in rats with perivascular and myocardial fibrosis. It has been reported that aldosterone may contribute to the development of cardiac fibrosis, but it is not known whether inhibition of NO synthesis affects angiotensin II (Ang II) receptor gene expression and aldosterone secretion. The aim of this study Was to investigate the effect of NO inhibition on the expression of Ang II receptors in the adrenal gland and on aldosterone secretion in rats. Wistar King A rats received normal water, L-NAME alone (1 mg/mL in the drinking water), or L-NAME and the α1- adrenergic receptor blocker bunazosin (0.1 mg/mL in the drinking water) for 1 week. After 1 week of treatment with L-NAME, systolic blood pressure, plasma aldosterone concentration (PAC), and mRNA level and number of Ang II type 1 receptor (AT1-R) were increased. Plasma renin activity, serum angiotensin- converting enzyme activity, and the number of AT2-R were unchanged. Although addition of bunazosin to L-NAME restored systolic blood pressure to the control level, PAC and AT1-R numbers remained significantly higher than those of control level. These results suggest that the increased AT1-R number and PAC induced by the inhibition of NO synthesis were independent of blood pressure and systemic renin-angiotensin system. Therefore, hypertension and myocardial fibrosis induced by NO blockade may be due in part to an elevation of PAC caused by increased AT1-R in the adrenal gland.

AB - We recently reported that administration of N(ω)-nitro-L-arginine methyl ester (L-NAME), an inhibitor of nitric oxide (NO) production, activates the vascular and cardiac renin-angiotensin systems and causes vascular thickening and myocardial hypertrophy in rats with perivascular and myocardial fibrosis. It has been reported that aldosterone may contribute to the development of cardiac fibrosis, but it is not known whether inhibition of NO synthesis affects angiotensin II (Ang II) receptor gene expression and aldosterone secretion. The aim of this study Was to investigate the effect of NO inhibition on the expression of Ang II receptors in the adrenal gland and on aldosterone secretion in rats. Wistar King A rats received normal water, L-NAME alone (1 mg/mL in the drinking water), or L-NAME and the α1- adrenergic receptor blocker bunazosin (0.1 mg/mL in the drinking water) for 1 week. After 1 week of treatment with L-NAME, systolic blood pressure, plasma aldosterone concentration (PAC), and mRNA level and number of Ang II type 1 receptor (AT1-R) were increased. Plasma renin activity, serum angiotensin- converting enzyme activity, and the number of AT2-R were unchanged. Although addition of bunazosin to L-NAME restored systolic blood pressure to the control level, PAC and AT1-R numbers remained significantly higher than those of control level. These results suggest that the increased AT1-R number and PAC induced by the inhibition of NO synthesis were independent of blood pressure and systemic renin-angiotensin system. Therefore, hypertension and myocardial fibrosis induced by NO blockade may be due in part to an elevation of PAC caused by increased AT1-R in the adrenal gland.

UR - http://www.scopus.com/inward/record.url?scp=0031705422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031705422&partnerID=8YFLogxK

U2 - 10.1161/01.HYP.32.3.527

DO - 10.1161/01.HYP.32.3.527

M3 - Article

C2 - 9740621

AN - SCOPUS:0031705422

VL - 32

SP - 527

EP - 533

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 3

ER -